These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30362099)

  • 1. Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.
    Chang KC; Petrash JM
    Adv Exp Med Biol; 2018; 1032():173-202. PubMed ID: 30362099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis of aldose reductase in diabetic complications.
    Chung SS; Chung SK
    Curr Med Chem; 2003 Aug; 10(15):1375-87. PubMed ID: 12871135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase expression as a risk factor for cataract.
    Snow A; Shieh B; Chang KC; Pal A; Lenhart P; Ammar D; Ruzycki P; Palla S; Reddy GB; Petrash JM
    Chem Biol Interact; 2015 Jun; 234():247-53. PubMed ID: 25541468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
    Brogard JM; Caro-Sampara F; Blicklé JF
    Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on molecules: aldose reductase.
    Anil Kumar P; Bhanuprakash Reddy G
    Exp Eye Res; 2007 Dec; 85(6):739-40. PubMed ID: 16997295
    [No Abstract]   [Full Text] [Related]  

  • 7. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIH conference. Aldose reductase and complications of diabetes.
    Cogan DG; Kinoshita JH; Kador PF; Robison G; Datilis MB; Cobo LM; Kupfer C
    Ann Intern Med; 1984 Jul; 101(1):82-91. PubMed ID: 6203454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase in diabetic complications of the eye.
    Kinoshita JH; Fukushi S; Kador P; Merola LO
    Metabolism; 1979 Apr; 28(4 Suppl 1):462-9. PubMed ID: 45423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
    Kador PF; Wyman M; Oates PJ
    Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols.
    Chethan S; Dharmesh SM; Malleshi NG
    Bioorg Med Chem; 2008 Dec; 16(23):10085-90. PubMed ID: 18976928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
    Chang KC; Li L; Sanborn TM; Shieh B; Lenhart P; Ammar D; LaBarbera DV; Petrash JM
    J Nat Prod; 2016 May; 79(5):1439-44. PubMed ID: 27140653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
    Sampath C; Sang S; Ahmedna M
    Biomed Pharmacother; 2016 Dec; 84():502-513. PubMed ID: 27685794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase inhibitors and diabetic complications.
    Raskin P; Rosenstock J
    Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between aldose reductase enzyme and the signaling pathway of protein kinase C in an in vitro diabetic retinopathy model.
    Sarikaya M; Yazihan N; Daş Evcimen N
    Can J Physiol Pharmacol; 2020 Apr; 98(4):243-251. PubMed ID: 31743046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibitors and cataract.
    Crabbe MJ
    Int Ophthalmol; 1991 Jan; 15(1):25-36. PubMed ID: 1901300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach against sugar cataract through aldose reductase inhibitors.
    Banditelli S; Boldrini E; Vilardo PG; Cecconi I; Cappiello M; Dal Monte M; Marini I; Del Corso A; Mura U
    Exp Eye Res; 1999 Nov; 69(5):533-8. PubMed ID: 10548473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does aldose reductase have a role in the development of the ocular complications of diabetes?
    Lightman S
    Eye (Lond); 1993; 7 ( Pt 2)():238-41. PubMed ID: 7607342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.